Abstract
8-Azapurine nucleus is a bioisoster of the purine nucleus. Variously substituted 8-azapurines have been synthesised and studied for their interactions with many enzymes and receptors and for their antitumor and antiviral activity. In this paper the main results of the studies made in these last years on this topic are reported.
Keywords: 8-Azapurines, 1,2,3-triazolo[4,5-d]pyrimidines, adenosine deaminase inhibitors, xanthine oxidase inhibitors, adenosine receptor ligands, antitumor and antiviral agents
Mini-Reviews in Medicinal Chemistry
Title: 8-Azapurine Nucleus: A Versatile Scaffold for Different Targets
Volume: 9 Issue: 12
Author(s): I. Giorgi and V. Scartoni
Affiliation:
Keywords: 8-Azapurines, 1,2,3-triazolo[4,5-d]pyrimidines, adenosine deaminase inhibitors, xanthine oxidase inhibitors, adenosine receptor ligands, antitumor and antiviral agents
Abstract: 8-Azapurine nucleus is a bioisoster of the purine nucleus. Variously substituted 8-azapurines have been synthesised and studied for their interactions with many enzymes and receptors and for their antitumor and antiviral activity. In this paper the main results of the studies made in these last years on this topic are reported.
Export Options
About this article
Cite this article as:
Giorgi I. and Scartoni V., 8-Azapurine Nucleus: A Versatile Scaffold for Different Targets, Mini-Reviews in Medicinal Chemistry 2009; 9 (12) . https://dx.doi.org/10.2174/138955709789957440
DOI https://dx.doi.org/10.2174/138955709789957440 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Optimising the Use of Non-Invasive Ventilation in the Intensive Care Setting
Current Respiratory Medicine Reviews An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy
Current Drug Safety Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets CAM Use in Pediatric Oncology
Current Pediatric Reviews Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?
Current Protein & Peptide Science Chemo-drug Controlled-release Strategies of Nanocarrier in the Development of Cancer Therapeutics
Current Medicinal Chemistry Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”?
Current Vascular Pharmacology Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety